• 1
    Roodman GD 1996 Advances in bone biology: The osteoclast. Endocrine Revs 17: 308332.
  • 2
    Mundy GR 1992 Cytokines and local factors which affect osteoclast function. Intl J Cell Cloning 10: 215222.
  • 3
    de Vernejoul MC 1996 Dynamics of bone remodeling: Biochemical and pathophysiological basis. Eur J Clin Chem Clin Biochem 34: 729734.
  • 4
    Gowen M 1992 Cytokines and Bone Metabolism. CRC Press, Boca Raton, FL
  • 5
    Riancho J, Mundy G 1995 The role of cytokines and growth factors as mediators of the effects of systemic hormones at the bone local level. Crit Revs Eukar Gene Express 5: 193217.
  • 6
    Collin-Osdoby P, Nickols G, Osdoby P 1995 Bone cell function, regulation, and communication: A role for nitric oxide. J Cell Biochem 57: 399408.
  • 7
    Evans C, Stefanovic-Racic, Lancaster J 1995 Nitric oxide and its role in orthopaedic disease. Clin Orthopaed Rel Res 312: 275294.
  • 8
    Collin-Osdoby P, Osdoby P 1996 The role of nitric oxide in regulating bone remodeling. In: Biological Mechanisms of Tooth Movement and Craniofacial Adaptation. Eds. ZDavidovitch, LNorton. EBSCO Media, Birmingham, Alabama. pp. 6982
  • 9
    Evans D, Ralston S 1996 Nitric oxide and bone. J Bone Miner Res 11: 300305.
  • 10
    Hall T, Chambers T 1996 Molecular aspects of osteoclast function. Inflamm Res 45: 19.
  • 11
    Danziger R, Zuckerbraun B, Pensler J 1997 Role of nitric oxide in the regulation of osteoblast metabolism. Plastic and Reconstruc Surg 100: 670673.
  • 12
    Griffith O, Steuhr D 1995 Nitric oxide synthases: Properties and catalytic mechanisms. Ann Rev Physiol 57: 707736.
  • 13
    Knowles R, Moncada S 1994 Nitric oxide synthases in mammals. Biochem J 298: 249258.
  • 14
    Bredt D, Snyder S 1994 Nitric oxide: A physiologic messenger molecule. Ann Rev Biochem 63: 175195.
  • 15
    Ralston S, Todd D, Helfrich M, Benjamin N, Grabowski P 1994 Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinol 135: 330336.
  • 16
    Damoulis P, Hauschka P 1994 Cytokines induce nitric oxide production in mouse osteoblasts. Biochem Biophys Res Communs 201: 924931.
  • 17
    Hukkanen M, Hughes F, Buttery L, Gross S, Evans T, Seddon S, Riveros-Moreno V, MacIntyre I, Polak J 1995 Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat, and human osteoblast-like cells and its functional role in osteoblast metabolic activity. Endocrinol 136: 54455453.
  • 18
    Brandi M, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross S, Polak J, MacIntyre I 1995 Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA 92: 29542958.
  • 19
    Sunyer T, Rothe L, Kirsch D, Jiang X, Anderson F, Osdoby P, Collin-Osdoby P 1997 Ca2+ or phorbol ester but not inflammatory stimuli elevate inducible nitric oxide synthase messenger ribonucleic acid and nitric oxide (NO) release in avian osteoclasts: Autocrine NO mediates Ca2+-inhibited bone resorption. Endocrinol 138: 21482162.
  • 20
    Helfrich M, Evans D, Grabowski P, Pollock J, Ohshima H, Ralston S 1997 Expression of nitric oxide synthase isoforms in bone and bone cell cultures. J Bone Miner Res 12: 11081115.
  • 21
    MacIntyre I, Zaidi M, Alam A, Datta H, Moonga B, Lidbury P, Hecker M, Vane J 1991 Osteoclastic inhibition: An action of nitric oxide not mediated by cGMP. Proc Natl. Acad Sci USA 88: 29362940.
  • 22
    Kasten T, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko T, Settle S, Currie M, Nickols G 1994 Potentiation of osteoclast bone resorptive activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci USA 91: 35693573.
  • 23
    Mancini L, Moradi-Bidhendi N, Brandi ML, MacIntyre I 1998 Nitric oxide, superoxide and peroxynitrite modulate osteoclast activity. Biochem Biophys Res Commun 243: 785790.
  • 24
    Lowik C, Nibbering P, van de Ruit M, Papapoulos S 1994 Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest 93: 14651472.
  • 25
    Ralston S, Ho L, Helfrich M, Grabowski P, Johnston P, Benjamin N 1995 Nitric oxide: A cytokine-induced regulator of bone resorption. J Bone Miner Res 10: 10401049.
  • 26
    Ralston SH, Grabowski PS 1996 Mechanisms of cytokine induced bone resorption: Role of nitric oxide, cyclic guanosine monophosphate, and prostaglandins. Bone 19: 2933.
  • 27
    Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C 1996 Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 18: 301304.
  • 28
    Tsukahara H, Miura M, Tsuchida S, Hata I, Hata K, Yamamoto K, Ishii Y, Muramatsu I, Sudo M 1996 Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats. Am J Physiol 270: E840E845.
  • 29
    Ralston S, Todd D, Helfrich M, Benjamin N, Grabowski P 1994 Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinol 135: 330336.
  • 30
    Collin-Osdoby P, Oursler M, Rothe L, Webber D, Anderson F, Osdoby P 1995 Osteoclast 121F antigen expression during osteoblast conditioned medium induction of osteoclast-like cells in vitro: relationship to calcitonin responsiveness, tartrate resistant acid phosphatase levels, and bone resorptive activity. J Bone Miner Res 10: 4558.
  • 31
    Sunyer T, Rothe L, Jiang X-S, Osdoby P, Collin-Osdoby P 1996 Pro-inflammatory agents, IL-8 and IL-10 upregulate inducible nitric oxide synthase expression and nitric oxide production in avian osteoclast-like cells. J Cell Biochem 60: 469483.
  • 32
    Webber D, Osdoby P, Hauschka P, Krukowski M 1990 Correlation of an osteoclast antigen and ruffled border on giant cells formed in response to resorbable substrates. J Bone Miner Res 5: 401410.
  • 33
    Webber D, Menton D, Osdoby P 1990 An in vivo model system for the study of avian osteoclast recruitment and activity. Bone Miner 11: 127140.
  • 34
    Krukowski M, Kahn A 1982 Inductive specificity of mineralized bone matrix in ectopic osteoclast differentiation. Calcif Tiss Intl 34: 474479.
  • 35
    Nguyen M, Shing Y, Folkman J 1993 Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47: 3140.
  • 36
    Cao Y, Chen C, Weatherbee J, Tsang M, Folkman J 1995 Gro-b, α—C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med 182: 20692077.
  • 37
    Iruela-Arispe M, Lane T, Redmond D, Reilly M, Bolender R, Kavanagh T, Sage E 1995 Expression of SPARC during development of the chicken chorioallantoic membrane: Evidence for regulated proteolysis in vivo. Molec Biol Cell 6: 327343.
  • 38
    Pipili-Synetos E, Sakkoula E, Haralabopoulos G, Andriopoulou P, Peristeris P, Maragoudakis M 1994 Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 111: 894902.
  • 39
    Hatjikondi O, Ravazoula P, Kardamakis D, Dimopoulos J, Papaioannou S 1996 In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity. Br J Cancer 74: 19161923.
  • 40
    Collin-Osdoby P, Li L, Rothe L, Anderson F, Kirsch D, Oursler M, Osdoby P 1998 Inhibition of avian osteoclast bone resorption by monoclonal antibody 121F: A mechanism involving the osteoclast free radical system. J Bone Miner Res 13: 6778.
  • 41
    Oursler M, Bell L, Clevinger B, Osdoby P 1985 Identification of osteoclast-specific monoclonal antibodies. J Cell Biol 100: 15921600.
  • 42
    Oursler M, Li L, Osdoby P 1991 Purification and characterization of an osteoclast membrane glycoprotein with homology to manganese superoxide dismutase. J Cell Biochem 46: 219233.
  • 43
    Somerman M, Berry J, Khalkhali-Ellis Z, Osdoby P, Simpson R 1995 Enhanced expression of av integrin subunit and osteopontin during differentiation of HL-60 cells along the monocytic pathway. Exp Cell Res 216: 335341.
  • 44
    Khalkhali-Ellis Z, Collin-Osdoby P, Li L, Brandi M, Osdoby P 1997 A human homolog of the 150 kD avian osteoclast membrane antigen related to superoxide dismutase and essential for bone resorption is induced by developmental agents and opposed by estrogen in FLG 29.1 cells. Calcif Tiss Intl 60: 187193.
  • 45
    Zhu H, Ross FP, Cao X, Teitelbaum S 1996 Phorbol myristate acetate transactivates the avian β3 integrin gene and induces αvβ3 integrin expression. J Cell Biochem 61: 420429.
  • 46
    Lowry O, Rosebrough N, Farr A, Randall R 1951 Protein measurement with the folin phenol reagent. J Biol Chem 193: 265275.
  • 47
    Collin-Osdoby P, Anderson F, Maloney W, Osdoby P 1998 Isolation and cultivation of human osteoclasts and osteoclast-like cells. In: Human Cell Culture Manual. Vol. 4. Primary Hematopoietic Cells. KollerM, PalssonB, eds. Kluwer Academic Publishers, Boston, MA. (In press)
  • 48
    Gerber H, Vu T, Ryan A, Kowalski J, Werb Z, Ferrara N 1999 VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med 5: 623628.
  • 49
    Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 2731.
  • 50
    Papapetropoulos A, Desai K, Rudic R, Mayer B, Zhang R, Ruiz-Torres M, Garica-Cardena G, Madri J, Sessa W 1997 Nitric oxide synthase inhibitors attenuate transforming-growth-factor-b1-stimulated capillary organization in vitro. Am J Pathol 150: 18351844.
  • 51
    Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, Persico G 1996 Role of soluble mediators in angiogenesis. Eur J Cancer 32A: 24012412.
  • 52
    Collin-Osdoby P, Rothe L, Bekker S, Anderson F, Osdoby P 1998 Osteoclast recruitment, formation, and bone resorptive activity are increased in parallel with neoangiogenesis on the chick chorioallantoic membrane in response to the angiogenic peptides bFGF or IL-8. Bone 23(5S): SA094 (Abst).
  • 53
    Pipili-Synetos E, Papageorgiou A, Sakkoula E, Sotiropoulou G, Fotsis T, Karakiulakis G, Maragoudakis M 1995 Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 116: 18291834.
  • 54
    Keefer L, Nims R, Davies K, Wink D 1996 “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Meths Enzymol 268: 281293.
  • 55
    Feelisch M 1998 The use of nitric oxide donors in pharmacological studies. Naunyn-Schmiedeberg's Arch Pharmacol 358: 113122.
  • 56
    Holliday LS, Dean AD, Lin RH, Greenwald JE, Gluck SL 1997 Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism. Am J Physiol 272: F283F291.
  • 57
    Chae H, Park R, Chung H, Kang J, Kim M, Choi D, Bang B, Kim H 1997 Nitric oxide is a regulator of bone remodeling. J Pharm Pharmacol 49: 897902.
  • 58
    Jamal S, Browner W, Bauer D, Cummings S 1998 Intermittent use of nitrates increases bone mineral density: The study of osteoporotic fractures. J Bone Miner Res 13: 17551759.
  • 59
    Kenzora J, Steele R, Yosipovitch Z, Glimcher M 1978 Experimental osteonecrosis of the femoral head in adult rabbits. Clin Orthop 130: 846.
  • 60
    Thornton M, O'Sullivan G, Williams M, Hughes P 1997 Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids. Clin Radiol 52: 607612.
  • 61
    Glowacki J 1998 Angiogenesis in fracture repair. Clin Orthop 355S: S8289.
  • 62
    Mont M, Jones L, Einhorn T, Hungerford D, Reddi A 1998 Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop 355S: S314335.
  • 63
    Aluisio F, Urbaniak J 1998 Proximal femur fractures after free vascularized fibular grafting to the hip. Clin Orthop 356: 192201.